Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference
September 28, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference 28 September 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or...
Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development
September 01, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development 1 September 2021 LONDON, Silence Therapeutics plc,...
Silence Therapeutics to Participate in September Investor Conferences
August 25, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Participate in September Investor Conferences 25 August 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Silence Therapeutics Reports Half-Year 2021 Results
August 12, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Reports Half-Year 2021 Results Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a)Silence to...
Notice of half year results
July 15, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Notice of Half Year Results 15 July 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and...
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
May 25, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration Companies on-track to initiate work on five targets within the first...
Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers
May 19, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers Data showed SLN124, an siRNA which targets TMPRSS6, was safe and effective in reducing plasma...
Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference
May 12, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference 12 May 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or...
Silence Therapeutics Launches New Video Game to Support International Thalassemia Day and Raise Disease Awareness
May 04, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Launches New Video Game to Support International Thalassemia Day and Raise Disease Awareness Play the free online game and share your score on social #BloodRunBeta Silence...
Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases
April 28, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases 28 April 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq:...